172 related articles for article (PubMed ID: 21904842)
1. Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.
Ipek Y; Fehmi H; Sevgi BK; Deniz S
J Thromb Thrombolysis; 2012 Feb; 33(2):197-201. PubMed ID: 21904842
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis in multiple myeloma.
Kristinsson SY
Hematology Am Soc Hematol Educ Program; 2010; 2010():437-44. PubMed ID: 21239832
[TBL] [Abstract][Full Text] [Related]
3. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.
Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM
J Thromb Haemost; 2003 Mar; 1(3):445-9. PubMed ID: 12871448
[TBL] [Abstract][Full Text] [Related]
4. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
5. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
Kristinsson SY; Björkholm M; Schulman S; Landgren O
Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Zonder JA; Barlogie B; Durie BG; McCoy J; Crowley J; Hussein MA
Blood; 2006 Jul; 108(1):403; author reply 404. PubMed ID: 16790586
[No Abstract] [Full Text] [Related]
7. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Uaprasert N; Voorhees PM; Mackman N; Key NS
Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
[TBL] [Abstract][Full Text] [Related]
8. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Minnema MC; Breitkreutz I; Auwerda JJ; van der Holt B; Cremer FW; van Marion AM; Westveer PH; Sonneveld P; Goldschmidt H; Lokhorst HM
Leukemia; 2004 Dec; 18(12):2044-6. PubMed ID: 15470485
[No Abstract] [Full Text] [Related]
9. Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
Maharaj S; Chang S; Seegobin K; Serrano-Santiago I; Zuberi L
Expert Rev Anticancer Ther; 2017 Jul; 17(7):585-591. PubMed ID: 28508703
[TBL] [Abstract][Full Text] [Related]
10. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Hussein MA
Thromb Haemost; 2006 Jun; 95(6):924-30. PubMed ID: 16732369
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
Shin J; Lee JJ; Kim K; Min CK; Lee JO; Suh C; Kim JS; Lee YJ; Yoon SS; Jo JC; Lee HS; Bang SM;
Int J Hematol; 2019 Jan; 109(1):79-90. PubMed ID: 30291558
[TBL] [Abstract][Full Text] [Related]
13. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
de Moreuil C; Ianotto JC; Eveillard JR; Carrier M; Delluc A
Rev Med Interne; 2016 Jul; 37(7):473-9. PubMed ID: 26833146
[TBL] [Abstract][Full Text] [Related]
14. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Zangari M; Saghafifar F; Anaissie E; Badros A; Desikan R; Fassas A; Mehta P; Morris C; Toor A; Whitfield D; Siegel E; Barlogie B; Fink L; Tricot G
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):187-92. PubMed ID: 11943931
[TBL] [Abstract][Full Text] [Related]
15. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdrè L; Palareti G; Masini L; Tura S; Baccarani M
Blood; 2002 Sep; 100(6):2272-3. PubMed ID: 12229885
[No Abstract] [Full Text] [Related]
16. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
17. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
19. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.
Fotiou D; Sergentanis TN; Papageorgiou L; Stamatelopoulos K; Gavriatopoulou M; Kastritis E; Psaltopoulou T; Salta S; Van Dreden P; Sangare R; Larsen AK; Terpos E; Elalamy I; Dimopoulos MA; Gerotziafas GT
Blood Cancer J; 2018 Nov; 8(11):102. PubMed ID: 30405097
[TBL] [Abstract][Full Text] [Related]
20. Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
Isoda A; Sato N; Miyazawa Y; Matsumoto Y; Koumoto M; Ookawa M; Sawamura M; Matsumoto M
Int J Hematol; 2015 Sep; 102(3):271-7. PubMed ID: 26177588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
